Patent application number | Description | Published |
20080221212 | TOPICAL FORMULATION - There is described a topical formulation. The topical formulation includes: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. | 09-11-2008 |
20100029769 | TOPICAL FORMULATION - There is described a topical formulation. The topical formulation comprises: (i) diclofenac or a pharmaceutically acceptable salt thereof, (ii) a first compound, and (iii) a second compound. The first compound and second compound are different, and each is selected from the group consisting essentially of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. It has been discovered that certain combination of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of diclofenac or a pharmaceutically acceptable salt thereof. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. | 02-04-2010 |
20110028460 | TOPICAL FORMULATION - It has been discovered that certain combinations compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) at least one active agent; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. | 02-03-2011 |
20120214874 | PHARMACEUTICAL FORMULATIONS AND METHODS OF USE - In one embodiment, the present invention provides a topical composition including a topically acting anesthetic active ingredient; an ester; a non-ionic surfactant; a polar solvent; water, and optionally a buffer, a pH adjusting agent or an anti-oxidant. The compositions are useful for alleviating pain especially associated with acute herpes zoster. | 08-23-2012 |
20120232152 | TOPICAL IBUPROFEN FORMULATIONS - The present application relates to a topical formulation comprising ibuprofen, a hydroalcoholic based solvent system, a C | 09-13-2012 |
20120309843 | HIGHLY PERMEATING TERBINAFINE FORMULATION - The present invention provides topical compositions, methods of preparation, and methods of treatment for onychomychosis. In certain specific embodiments, the invention provides an anti-fungal pharmaceutical composition for topical application comprising an anti-fungal agent, a zwitterionic surfactant or charged derivative thereof; a carboxylic acid, a lower alcohol, and water. The acid is selected from a short-chain hydroxy acid, a short-chain fatty acid, and a mixture thereof. In certain other specific embodiments, the invention provides an anti-fungal pharmaceutical composition for topical application comprising an anti-fungal agent, a quarternary amino acid, a keratolytic agent; a lower alcohol; and water. In certain embodiments, the keratolytic agent is urea, ammonium thioglycolate, or a mixture thereof. | 12-06-2012 |
20130079404 | TOPICAL FORMULATION - It has been discovered that certain combinations of compounds are excellent penetration enhancers and, as such, can be incorporated in a topical formulation to facilitate administration of active agents. The increased penetration enhancement can also lead to a reduction in the total concentration of skin irritants in the formulation. There is described herein a topical formulation comprising (i) an active agent selected from at least one of lidocaine and tetracaine; (ii) a first compound, and (iii) a second compound, wherein the first compound and second compound are different, and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate and sodium lauryl sulfoacetate. | 03-28-2013 |
20130136805 | FOAMABLE COMPOSITIONS OF STABILIZED CHLORITE - The present application relates to foamable compositions and foams comprising stabilized chlorite, including stabilized chlorite solutions such as Oxovasin™, and to medical uses thereof, in particular for wound healing. The foamable compositions comprise at least one foaming agent, stabilized chlorite, water and optionally, a buffering agent. | 05-30-2013 |
20130177629 | LIPOSOMAL COMPOSITIONS - The present application includes liposomes and liposomal compositions that comprise chlorite, chlorate or a mixture thereof entrapped inside the liposome core, methods for their preparation and methods of use, in particular as medicaments. | 07-11-2013 |
20130243701 | FOAMABLE FORMULATION - The present invention provides DMSO-containing foamable formulations, methods for preparation, and methods of treatment. The formulations can provide good permeability and bioavailability at the target site. Preferably, the formulations are useful for treating osteoarthritis. In one embodiment, the invention provides a foamable formulation for topical use, said formulation comprising DMSO, polyalkylene glycol alkyl ether, an active agent, a monohydric lower alcohol, a diol, and water. Preferably, the active agent is a non-steroidal anti-inflammatory drug, such as diclofenac sodium or ibuprofen. | 09-19-2013 |
20130316020 | WOUND DRESSINGS COMPRISING CHLORITE - This application described a wound dressing comprising an absorbent material, an effective amount of chlorite and an amount of a base to provide a pH of the dressing material greater than or equal to about ( | 11-28-2013 |
20130337031 | TOPICAL FORMULATIONS, SYSTEMS AND METHODS - The present disclosure is drawn to topical formulations, transdermal systems, and related methods. In one embodiment, a topical formulation is provided that includes a local anesthetic, a first compound, and a second compound. The first compound and second compound are different and each is selected from the group consisting of N-lauroyl sarcosine, sodium octyl sulfate, methyl laurate, isopropyl myristate, oleic acid, glyceryl oleate, and sodium lauryl sulfoacetate. | 12-19-2013 |